NHSE Interim treatment options

Message from Steve Williamson, NHS England Lead Cancer Pharmacist

29th April 2020 – NHSE Interim treatment options

 

Dear Colleague

You may have seen that NICE has published an updated table to the SACT clinical guideline NG161 listing many new Interim treatment options earlier this week. See https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381. There are a couple of points of clarification for providers to note:

  • Enzalutamide for prostate cancer states it is subject to confirmation, we can confirm enzalutamide is approved, and there is no need to check for confirmation. A Blueteq form for abiraterone for patients unable to tolerate enzalutamide will be made available in due course.
  • Gilteritinib is approved for relapsed /refractory AML and not newly diagnosed AML.
  • Nivolumab is approved in MSI-H colorectal cancer, the wording states ‘subject to confirmation’ we can confirm this is approved and there is no need to check for confirmation.
  • A blueteq form for polatuzumab will be released in due course as NHSE is currently working with the company to ensure there is stock available for the selected patient group.

We advise all these indications are to be billed through the usual specialised commissioning route, as there is additional COVID19 funding available for them.  Any drugs where we have changed the CDF pathway are not funded through CDF as there is separate COVID19 funding for them. We are pleased to note that the manufacturers of many of these drugs have worked with NHS England and offered additional discounts to support the NHS during COVID19.

Latest News

By BOPA Committee on 12th July 2024

TRANScribing: Clinical considerations for safe and inclusive prescribing for transgender and non-binary patients

BOPA is delighted to announce the publication of TRANScribing: Clinical considerations for safe and inclusive prescribing for transgender and non-binary patients in collaboration with OUTpatients. It is estimated that one…

Read article
By BOPA Committee on 11th July 2024

Round Table Discussion at #BOPA2024

  As an exciting addition to the 2024 conference, we invite you all to participate in one of our interactive sessions on the Sunday morning. We have a lineup of…

Read article
By BOPA Committee on 10th July 2024

APTUK Position Statement for DHSC PGD Update

The Association of Pharmacy Technicians UK (APTUK), as the professional leadership body for pharmacy technicians, welcome the positive outcome of the DHSC consultation supporting the enabling of registered pharmacy technicians…

Read article
By BOPA Research on 9th July 2024

Last Chance to Submit Your Work to #BOPA2024

Last Chance to Submit: BOPA 2024 Abstract Submission DEADLINE is 14th July 2024. Delegates are invited to present results of their clinical and technical work as a poster with some…

Read article